Establishment Labs (NASDAQ:ESTA) Reaches New 12-Month High – Still a Buy?

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) hit a new 52-week high on Thursday . The stock traded as high as $51.06 and last traded at $50.98, with a volume of 144765 shares changing hands. The stock had previously closed at $49.85.

Analyst Ratings Changes

Several research analysts recently weighed in on ESTA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Establishment Labs in a research report on Wednesday, October 8th. Citigroup reissued a “neutral” rating on shares of Establishment Labs in a report on Tuesday, October 7th. Wall Street Zen raised Establishment Labs from a “sell” rating to a “hold” rating in a report on Sunday, October 19th. Canaccord Genuity Group initiated coverage on Establishment Labs in a report on Wednesday, August 20th. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, Mizuho raised their price objective on Establishment Labs from $58.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $56.50.

Establishment Labs Price Performance

The company has a debt-to-equity ratio of 9.71, a current ratio of 2.84 and a quick ratio of 1.67. The stock has a 50 day moving average price of $41.41 and a 200-day moving average price of $38.75. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -16.09 and a beta of 0.85.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). The firm had revenue of $51.30 million during the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The business’s revenue was up 16.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.62) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. On average, analysts forecast that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Institutional Trading of Establishment Labs

A number of institutional investors have recently made changes to their positions in ESTA. Geode Capital Management LLC boosted its stake in Establishment Labs by 1.2% during the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after buying an additional 299 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in Establishment Labs by 5.2% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 6,025 shares of the company’s stock worth $257,000 after buying an additional 300 shares during the last quarter. Raymond James Financial Inc. boosted its stake in Establishment Labs by 0.4% during the first quarter. Raymond James Financial Inc. now owns 119,752 shares of the company’s stock worth $4,886,000 after buying an additional 491 shares during the last quarter. Swiss National Bank boosted its stake in Establishment Labs by 1.3% during the first quarter. Swiss National Bank now owns 39,000 shares of the company’s stock worth $1,591,000 after buying an additional 500 shares during the last quarter. Finally, CWM LLC boosted its stake in Establishment Labs by 45.9% during the second quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after buying an additional 686 shares during the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.